- Home
- CRDF vs TGE Comparison
CRDF vs TGE Comparison
Compare CRDF & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- TGE
- Stock Information
- Founded
- CRDF 1999
- TGE 2023
- Country
- CRDF United States
- TGE France
- Employees
- CRDF N/A
- TGE N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- TGE Newspapers/Magazines
- Sector
- CRDF Health Care
- TGE Consumer Discretionary
- Exchange
- CRDF Nasdaq
- TGE Nasdaq
- Market Cap
- CRDF 144.4M
- TGE 120.2M
- IPO Year
- CRDF N/A
- TGE N/A
- Fundamental
- Price
- CRDF $2.20
- TGE $2.12
- Analyst Decision
- CRDF Strong Buy
- TGE
- Analyst Count
- CRDF 5
- TGE 0
- Target Price
- CRDF $11.10
- TGE N/A
- AVG Volume (30 Days)
- CRDF 762.3K
- TGE 1.1M
- Earning Date
- CRDF 11-06-2025
- TGE 02-12-2020
- Dividend Yield
- CRDF N/A
- TGE N/A
- EPS Growth
- CRDF N/A
- TGE N/A
- EPS
- CRDF N/A
- TGE 1.64
- Revenue
- CRDF $545,000.00
- TGE $77,014,000.00
- Revenue This Year
- CRDF N/A
- TGE N/A
- Revenue Next Year
- CRDF N/A
- TGE N/A
- P/E Ratio
- CRDF N/A
- TGE $1.28
- Revenue Growth
- CRDF N/A
- TGE 81.03
- 52 Week Low
- CRDF $1.90
- TGE $1.93
- 52 Week High
- CRDF $5.64
- TGE $37.02
- Technical
- Relative Strength Index (RSI)
- CRDF 52.58
- TGE N/A
- Support Level
- CRDF $1.99
- TGE N/A
- Resistance Level
- CRDF $2.13
- TGE N/A
- Average True Range (ATR)
- CRDF 0.10
- TGE 0.00
- MACD
- CRDF 0.04
- TGE 0.00
- Stochastic Oscillator
- CRDF 78.69
- TGE 0.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.